Hyderabad, Mar 21 (TNT): Dr. Reddy’s Laboratories on Saturday announced the launch of its injectable semaglutide, branded as Obeda®, marking India’s first generic version approved by the Drugs Controller General of India (DCGI) for the treatment of Type 2 diabetes.
In a release, the Hyderabad based pharma giant said the launch represents its entry into the segment immediately after patent expiry, aimed at expanding access to GLP-1 receptor agonist-based therapies for diabetes management.
India currently has over 101 million adults living with diabetes, with prevalence estimated at 11.4 per cent, while an additional 136 million individuals are pre-diabetic, indicating a significant and growing disease burden.
Semaglutide has a proven global track record in improving glycaemic control and aiding weight management as part of a comprehensive treatment plan.
In a Phase III clinical study involving 312 participants, Obeda® demonstrated non-inferior efficacy and a safety profile comparable to the innovator drug, with similar outcomes in glycaemic reduction, fasting and post-prandial glucose control, and HbA1c targets.
The drug is available in 2 mg and 4 mg strengths in a pre-filled disposable pen designed for once-weekly subcutaneous administration, with each pen delivering a minimum of four doses. The monthly cost has been fixed at ₹4,200.
The company said both API and formulation development were carried out in-house, reflecting its capabilities in complex product development and peptide science.
Dr Reddy’s Chief Executive Officer Erez Israeli said the launch strengthens the company’s portfolio in critical therapeutic areas and reinforces its commitment to making advanced diabetes treatments accessible and affordable.
As part of patient support, the company has introduced SemaKare™, a comprehensive programme offering digital assistance, counselling, injection training and therapy adherence monitoring.
The company also plans to establish metabolic centres of excellence across India to enhance diagnosis, treatment and patient awareness for diabetes and related metabolic disorders.
Obeda® is a prescription drug, and patients are advised to consult healthcare professionals before use.
TNT TS
Leave a Reply